BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ren D, Pichichero ME. Vaccine targets against Moraxella catarrhalis. Expert Opin Ther Targets 2016;20:19-33. [PMID: 26565427 DOI: 10.1517/14728222.2015.1081686] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ysebaert C, Castado C, Mortier MC, Rioux S, Feron C, Di Paolo E, Weynants V, Blais N, Devos N, Hermand P. UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen. Vaccine 2021;39:5641-9. [PMID: 34446318 DOI: 10.1016/j.vaccine.2021.08.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shi W, Wen D, Chen C, Yuan L, Gao W, Tang P, Cheng X, Yao K. β-Lactamase production and antibiotic susceptibility pattern of Moraxella catarrhalis isolates collected from two county hospitals in China. BMC Microbiol 2018;18:77. [PMID: 30029595 DOI: 10.1186/s12866-018-1217-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ren D, Almudevar AL, Murphy TF, Lafontaine ER, Campagnari AA, Luke-Marshall N, Pichichero ME. Serum antibody response to Moraxella catarrhalis proteins in stringently defined otitis prone children. Vaccine 2019;37:4637-45. [PMID: 28755833 DOI: 10.1016/j.vaccine.2017.07.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
4 Tzani-Tzanopoulou P, Skliros D, Megremis S, Xepapadaki P, Andreakos E, Chanishvili N, Flemetakis E, Kaltsas G, Taka S, Lebessi E, Doudoulakakis A, Papadopoulos NG. Interactions of Bacteriophages and Bacteria at the Airway Mucosa: New Insights Into the Pathophysiology of Asthma. Front Allergy 2020;1:617240. [PMID: 35386933 DOI: 10.3389/falgy.2020.617240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Li K, Liu X, Zhang X, Liu Z, Yu Y, Zhao J, Wang L, Kong Y, Chen M. Identification microbial glycans substructure associate with disease and species. Carbohydr Polym 2021;273:118595. [PMID: 34560996 DOI: 10.1016/j.carbpol.2021.118595] [Reference Citation Analysis]
6 Borges IC, Andrade DC, Cardoso MR, Toppari J, Vähä-Mäkilä M, Ilonen J, Knip M, Hyöty H, Veijola R, Simell O, Jartti T, Käyhty H, Ruuskanen O, Nascimento-Carvalho CM. Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life. Clin Vaccine Immunol 2016;23:878-83. [PMID: 27581439 DOI: 10.1128/CVI.00341-16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Santos-Cortez RLP, Bhutta MF, Earl JP, Hafrén L, Jennings M, Mell JC, Pichichero ME, Ryan AF, Tateossian H, Ehrlich GD. Panel 3: Genomics, precision medicine and targeted therapies. Int J Pediatr Otorhinolaryngol 2020;130 Suppl 1:109835. [PMID: 32007292 DOI: 10.1016/j.ijporl.2019.109835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Murphy TF, Kirkham C, Johnson A, Brauer AL, Koszelak-Rosenblum M, Malkowski MG. Sulfate-binding protein, CysP, is a candidate vaccine antigen of Moraxella catarrhalis. Vaccine 2016;34:3855-61. [PMID: 27265455 DOI: 10.1016/j.vaccine.2016.05.045] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
9 Sun X, Zhang B, Xu G, Chen J, Shang Y, Lin Z, Yu Z, Zheng J, Bai B. In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis. Ann Lab Med 2021;41:293-301. [PMID: 33303714 DOI: 10.3343/alm.2021.41.3.293] [Reference Citation Analysis]
10 Thibau A, Dichter AA, Vaca DJ, Linke D, Goldman A, Kempf VAJ. Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets. Med Microbiol Immunol 2020;209:243-63. [PMID: 31788746 DOI: 10.1007/s00430-019-00649-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Soltan MA, Elbassiouny N, Gamal H, Elkaeed EB, Eid RA, Eldeen MA, Al-Karmalawy AA. In Silico Prediction of a Multitope Vaccine against Moraxella catarrhalis: Reverse Vaccinology and Immunoinformatics. Vaccines (Basel) 2021;9:669. [PMID: 34207238 DOI: 10.3390/vaccines9060669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Augustyniak D, Seredyński R, McClean S, Roszkowiak J, Roszniowski B, Smith DL, Drulis-Kawa Z, Mackiewicz P. Virulence factors of Moraxella catarrhalis outer membrane vesicles are major targets for cross-reactive antibodies and have adapted during evolution. Sci Rep 2018;8:4955. [PMID: 29563531 DOI: 10.1038/s41598-018-23029-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
13 Pichichero ME. Ten-Year Study of Acute Otitis Media in Rochester, NY. Pediatr Infect Dis J 2016;35:1027-32. [PMID: 27182898 DOI: 10.1097/INF.0000000000001216] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
14 Ren D, Bajorski P, Murphy TF, Lafontaine ER, Pichichero ME. Synchrony in serum antibody response to conserved proteins of Moraxella catarrhalis in young children. Hum Vaccin Immunother 2020;16:3194-200. [PMID: 32401688 DOI: 10.1080/21645515.2020.1752562] [Reference Citation Analysis]
15 Blakeway LV, Tan A, Peak IRA, Seib KL. Virulence determinants of Moraxella catarrhalis: distribution and considerations for vaccine development. Microbiology (Reading) 2017;163:1371-84. [PMID: 28893369 DOI: 10.1099/mic.0.000523] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
16 Pizzutto SJ, Hare KM, Upham JW. Bronchiectasis in Children: Current Concepts in Immunology and Microbiology. Front Pediatr 2017;5:123. [PMID: 28611970 DOI: 10.3389/fped.2017.00123] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 6.2] [Reference Citation Analysis]
17 Tan A, Blakeway LV, Bakaletz LO, Boitano M, Clark TA, Korlach J, Jennings MP, Peak IR, Seib KL. Complete Genome Sequence of Moraxella catarrhalis Strain CCRI-195ME, Isolated from the Middle Ear. Genome Announc 2017;5:e00384-17. [PMID: 28546484 DOI: 10.1128/genomeA.00384-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
18 Kowalski AP, Maboni G, Gressler LT, Espíndola JP, Balzan C, Tasca C, Guizzo JA, Conceição FR, Frandoloso R, de Vargas AC. Antigenic characterization of Moraxella bovis, Moraxella bovoculi and Moraxella ovis strains with potential use in vaccines. Vet Microbiol 2017;210:56-63. [PMID: 29103697 DOI: 10.1016/j.vetmic.2017.08.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
19 Yassin GM, Amin MA, Attia AS. Immunoinformatics Identifies a Lactoferrin Binding Protein A Peptide as a Promising Vaccine With a Global Protective Prospective Against Moraxella catarrhalis. J Infect Dis 2016;213:1938-45. [PMID: 26908723 DOI: 10.1093/infdis/jiw062] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
20 De Smedt P, Leroux-Roels G, Vandermeulen C, Tasciotti A, Di Maro G, Dozot M, Casula D, Annaratone M, Riccucci D, Arora AK. Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial. Vaccine X 2021;9:100124. [PMID: 34820619 DOI: 10.1016/j.jvacx.2021.100124] [Reference Citation Analysis]
21 Alderson MR, Murphy T, Pelton SI, Novotny LA, Hammitt LL, Kurabi A, Li JD, Thornton RB, Kirkham LS. Panel 8: Vaccines and immunology. Int J Pediatr Otorhinolaryngol 2020;130 Suppl 1:109839. [PMID: 31948716 DOI: 10.1016/j.ijporl.2019.109839] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
22 Singh S, Wilson JC, Cripps AW, Massa H, Ozberk V, Grice ID, Peak IR. Immunological characterisation of truncated lipooligosaccharide-outer membrane protein based conjugate vaccine against Moraxella catarrhalis and nontypeable Haemophilus influenzae. Vaccine 2020;38:309-17. [PMID: 31668366 DOI: 10.1016/j.vaccine.2019.10.014] [Reference Citation Analysis]